
Adaptimmune Therapeutics plc (Wed, May 01, 2024)

Sell candidate since May 01, 2024



StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania

score: **-1.43**

#12026/30053

Trend:	Sel
MV Long:	Sel
MV Short:	Buy
Pivot:	Buy
Volume:	Buy
MACD:	Buy

Tech commentaries:

The Adaptimmune Therapeutics plc stock price gained 1.68% on the last trading day (Wednesday, 1st May 2024), rising from \$1.19 to \$1.21. It has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 7.76% from a day low at \$1.16 to a day high of \$1.25. The price has risen in 7 of the last 10 days and is up by 22.59% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 256 thousand more shares were traded than the day before. In total, 911 thousand shares were bought and sold for approximately \$1.10 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -13.61% during the next 3 months and, with a 90% probability hold a price between \$0.744 and \$1.38 at the end of this 3-month period.

A buy signal was issued from a pivot bottom point on **Thursday, April 18, 2024**, and so far it has risen 34.68%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). **Adaptimmune Therapeutics plc** has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The **Adaptimmune Therapeutics plc** stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at \$1.28. On a fall, the stock will find some support from the short-term average at \$1.13. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Adaptimmune Therapeutics plc finds support from accumulated volume at \$1.17 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance from accumulated volume at **\$1.33**, **\$1.38** and **\$1.44**.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved **\$0.0900** between high and low, or **7.76%**. For the last week, the stock has had daily average volatility of **7.47%**.

Adaptimmune Therapeutics plc holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.

Risk: Very High

Evaluation: Call Candidate